

AMENDMENTS TO THE CLAIMS

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (canceled).

Claim 2 (currently amended): ~~Antibody~~The monoclonal antibody according to claim ~~1~~36, wherein the ~~disease is~~ monoclonal antibody binds to misfolded proteins that are specific to schizophrenia.

Claim 3 (currently amended): ~~Antibody~~The monoclonal antibody according to claim ~~1~~36, wherein the ~~disease is~~ monoclonal antibody binds to misfolded proteins that are specific to depression.

Claim 4 (currently amended): ~~Antibody~~The monoclonal antibody according to claim ~~1~~36, wherein the ~~disease is a~~ monoclonal antibody binds to misfolded proteins that are specific to bipolar affective disorder.

Claims 5-16 (cancelled)

Claim 17 (currently amended): ~~Antibody~~The monoclonal antibody according to claim ~~1~~36, wherein the monoclonal antibody is has been modified to be a blood-brain barrier-crossing monoclonal antibody.

Claim 18 (currently amended): ~~Antibody~~The binding fragment according to claim ~~1~~37, wherein the antibody binding fragment is cloned into a chimeric antibody or is combined with humanized antibody or human sequences.

Claim 19 (cancelled)

Claim 20 (currently amended): ~~Antibody~~The monoclonal antibody according to claim-1 36, wherein the monoclonal antibody is coupled to a pharmaceutically active substance.

Claim 21 (currently amended): ~~Antibody~~The monoclonal antibody according to claim-1 36, wherein the monoclonal antibody is coupled to an isotope or a radioactive labeled molecule.

Claims 22 and 23 (cancelled)

Claim 24 (withdrawn-currently amended): ~~Method~~A method for diagnosis of diagnosing a neuropsychiatric diseases, such as disease selected from the group consisting of schizophrenia or, depression or and bipolar affective disorder, by means of antibodies using a monoclonal antibody, or binding fragment thereof, produced from the hybridoma cell line deposited as DSM ACC2714 (mAB 9C9) that bind binds to misfolded proteins that are specific to said neuropsychiatric disease-specific proteins, in which said method comprising:

- a) ~~the antibodies are contacted with~~contacting a tissue or body fluid sample of a patient with said monoclonal antibody or binding fragment thereof[[,]]; and
- b) ~~detecting any~~any antibody-protein complexes thus formed, if any, are detected, and
- c) ~~wherein~~the presence, if applicable, of said antibody-protein complexes is considered to be a positive finding for a said neuropsychiatric disease, wherein
- d) ~~an antibody that recognizes misfolded proteins that can be assigned specifically to one of the diseases is used in the method.~~

Claim 25 (withdrawn-Previously presented): The method according to claim 24, wherein the presence of antibody-protein complexes is detected by means of ELISA, Western blotting or immuno-coupled fluorescence methods.

Claim 26 (canceled)

Claim 27 (withdrawn-Currently amended): The method according to claim 24, wherein the tissue or body fluid sample ~~to be tested~~ is liquor, urine, blood or serum.

Claim 28 (currently amended): A pharmaceutical preparation ~~that can be administered to a patient in a blood-brain barrier-crossing form for treatment of the neuropsychiatric diseases schizophrenia or depression or bipolar affective disorder comprising antibodies~~ the monoclonal antibody according to claim 1-36.

Claim 29 (currently amended): The pharmaceutical preparation according to claim 28, wherein the ~~antibodies are~~ monoclonal antibody is coupled to a pharmaceutically active ~~substances~~ substance.

Claim 30 (currently amended): The pharmaceutical preparation according to claim 28, wherein the ~~antibodies are~~ monoclonal antibody is coupled to ~~isotopes an isotope or a~~ radioactively labeled molecule.

Claims 31-35 (canceled)

Claim 36 (new): A monoclonal antibody produced from the hybridoma cell line deposited as DSM ACC2714 (mAB 9C9).

Claim 37 (new): A binding fragment of a monoclonal antibody produced from the hybridoma cell line deposited as DSM ACC2714 (mAB 9C9), wherein said binding fragment binds to misfolded proteins that are specific to neuropsychiatric diseases

selected from the group consisting of schizophrenia, depression and bipolar affected disorder.

Claim 38 (new): The binding fragment according to claim 37, wherein the binding fragment is coupled to a pharmaceutically active substance.

Claim 39 (new): The binding fragment according to claim 37, wherein the binding fragment is coupled to an isotope or a radioactive labeled molecule.